Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Orchard Therapeutics stock
Learn how to easily invest in Orchard Therapeutics stock.
Orchard Therapeutics plc is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 224 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Orchard Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ORTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Orchard Therapeutics stock price (NASDAQ: ORTX)Use our graph to track the performance of ORTX stocks over time.
Orchard Therapeutics shares at a glance
|Latest market close||$0.99|
|52-week range||$1.12 - $9.08|
|50-day moving average||$1.40|
|200-day moving average||$3.27|
|Wall St. target price||$9.79|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.21|
Buy Orchard Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Orchard Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Orchard Therapeutics price performance over time
|1 week (2022-01-19)||-5.76%|
|1 month (2021-12-23)||-25.60%|
|3 months (2021-10-26)||-47.65%|
|6 months (2021-07-26)||-66.46%|
|1 year (2021-01-26)||-83.43%|
|2 years (2020-01-24)||-92.50%|
|3 years (2019-01-25)||12.05|
|5 years (2017-01-22)||N/A|
Orchard Therapeutics financials
|Revenue TTM||$1.2 million|
|Gross profit TTM||$1.7 million|
|Return on assets TTM||-26.91%|
|Return on equity TTM||-63.28%|
|Market capitalisation||$155.6 million|
TTM: trailing 12 months
Orchard Therapeutics share dividends
We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.
Orchard Therapeutics share price volatility
Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $1.12 up to $9.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 1.1066. This would suggest that Orchard Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Orchard Therapeutics overview
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company has a strategic collaboration agreement with Pharming Group N. V.
Orchard Therapeutics in the news
Netflix shares fall near pre-pandemic level as investors fear slowing subscriber growth, competition
Stocks making the biggest moves midday: Netflix, Kohl's, Wynn Resorts, General Motors and more
RBC upgrades Comcast to outperform on subscriber growth
Frequently asked questionsWhat percentage of Orchard Therapeutics is owned by insiders or institutions?
Currently 0.118% of Orchard Therapeutics shares are held by insiders and 59.667% by institutions. How many people work for Orchard Therapeutics?
Latest data suggests 224 work at Orchard Therapeutics. When does the fiscal year end for Orchard Therapeutics?
Orchard Therapeutics's fiscal year ends in December. Where is Orchard Therapeutics based?
Orchard Therapeutics's address is: 108 Cannon Street, London, United Kingdom, EC4N 6EU What is Orchard Therapeutics's ISIN number?
Orchard Therapeutics's international securities identification number is: US68570P1012 What is Orchard Therapeutics's CUSIP number?
Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101
More guides on Finder
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Ask an Expert